SCHEMBL363162

SCHEMBL363162

CCc1c(OO)ccc2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NCEH1 Q6PIU2 3/20 0.60
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 4/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KDM4E B2RXH2 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
ALDH1A1 P00352 2/20 0.42
GAA P10253 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL220205 0.86 NCEH1 (0.61) NCEH1KMT2AMEN1MAPTCYP1A2
SCHEMBL18037716 0.86 NCEH1 (0.62) NCEH1KMT2AMEN1MAPTCYP1A2
SCHEMBL19231594 0.85 HSD17B10 (0.57) NCEH1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL11893003 0.83 KMT2A (0.60) NCEH1KMT2AMEN1MAPTSMN1; SMN2
SCHEMBL13244348 0.81 NCEH1 (0.56) NCEH1KMT2AMEN1MAPTKDM4E
SCHEMBL13888682 0.80 NCEH1 (0.71) NCEH1KMT2AMAPTKDM4EALDH1A1
SCHEMBL19002412 0.79 NCEH1 (0.54) NCEH1KMT2AMEN1CYP2C9TDP1
SCHEMBL22416830 0.78 MAPT (0.69) NCEH1KMT2AMEN1MAPTHSD17B10
SCHEMBL21872049 0.77 NCEH1 (0.52) NCEH1KMT2AMEN1MAPTKDM4E
SCHEMBL18209496 0.77 ALDH1A1 (0.62) NCEH1HSD17B10KDM4ETDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023132551-A1 SAND FOR DIAGNOSING STATE OF ANIMAL URINE, METHOD FOR MANUFACTURING SAME, AND URINE STATE DIAGNOSIS METHOD USING SAME 주식회사 퓨쳐바이오웍스 2023-07-13 WO claimed
EP-3237365-B1 CYCLOALKANE OXIDATION CATALYSTS AND METHOD TO PRODUCE ALCOHOLS AND KETONES RHODIA OPERATIONS (FR) 2018-11-28 EP claimed
EP-2877439-B1 CYCLOALKANE OXIDATION CATALYSTS AND METHOD TO PRODUCE ALCOHOLS AND KETONES RHODIA OPERATIONS (FR) 2018-02-14 EP claimed
US-20170349524-A1 Cycloalkane oxidation catalysts and method to produce alcohols and ketones BASF SE (DE) 2017-12-07 US claimed
EP-3237365-A1 CYCLOALKANE OXIDATION CATALYSTS AND METHOD TO PRODUCE ALCOHOLS AND KETONES Rhodia Operations (FR) 2017-11-01 EP claimed
US-9745239-B2 Cycloalkane oxidation catalysts and method to produce alcohols and ketones RHODIA OPERATIONS (FR) 2017-08-29 US claimed
US-9708238-B2 Cycloalkane oxidation catalysts and method to produce alcohols and ketones RHODIA OPERATIONS (FR) 2017-07-18 US claimed
EP-2986585-B1 CYCLOALKANE OXIDATION CATALYSTS AND METHOD TO PRODUCE ALCOHOLS AND KETONES RHODIA OPERATIONS (FR) 2017-06-21 EP claimed
WO-2016102343-A1 CYCLOALKANE OXIDATION CATALYSTS AND METHOD TO PRODUCE ALCOHOLS AND KETONES RHODIA OPERATIONS (FR) 2016-06-30 WO claimed
US-20160060199-A1 Cycloalkane oxidation catalysts and method to produce alcohols and ketones PERFORMANCE POLYAMIDES, SAS (FR) 2016-03-03 US claimed
EP-1490300-A1 TITANOSILICATE, PROCESS FOR ITS PRODUCTION, AND ITS USE IN PRODUCING OXIDIZED COMPOUND Showa Denko K.K. (JP) 2004-12-29 EP claimed
US-6759540-B2 FOR USE AS OXIDATION CATALYST IN OXIDATION REACTION OF A COMPOUND HAVING A CARBON-CARBON DOUBLE BOND AND A OTHER FUNCTIONAL GROUP WHEREIN THE CARBON-CARBON DOUBLE BOND OF COMPOUND IS OXIDIZED BY USING A PEROXIDE AS AN OXIDIZING AGENT SHOWA DENKO K.K. (JP) 2004-07-06 US claimed
US-20040122243-A1 Process for oxidizing carbon-carbon double bond and process for producing oxidized compounds SHOWA DENKO K.K. (JP) 2004-06-24 US claimed
US-20040034258-A1 Crystalline MWW-type titanosilicate catalyst for producing oxidized compound, production process for the catalyst, and process for producing oxidized compound by using the catalyst SHOWA DENKO K.K. 2004-02-19 US claimed
WO-2003074421-A1 TITANOSILICATE, PROCESS FOR ITS PRODUCTION, AND ITS USE IN PRODUCING OXIDIZED COMPOUND SHOWA DENKO K. K. (JP) 2003-09-12 WO claimed
EP-1324948-A2 CRYSTALLINE MWW-TYPE TITANOSILICATE, ITS PREPARATION AND USE THEREOF FOR PRODUCING EPOXIDES Showa Denko K.K. (JP) 2003-07-09 EP claimed
US-20030040649-A1 Crystalline mww-type titanosilicate catalyst for producing oxidized compound, production process for the catalyst, and process for producing oxidized compound by using the catalyst SHOWA DENKO K.K. (JP) 2003-02-27 US claimed
US-6500955-B1 CONDENSING A HALO- QUINOLINE WITH AN ALPHA-PICOLYL DERIVATIVES IN THE PRESENCE OF A SOLVENT AND A PHASE TRANSFER CATALYST AT -10 TO 90 DEGREE C. TO FORM (2,8-BIS (TRIFLUOROMETHYL)-4-QUINOLINYL)-2-PYRIDINYLMETHANONE NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) 2002-12-31 US claimed
US-20020188129-A1 ONE POT SYNTHESIS OF [2, 8-BIS (TRIFLUOROMETHYL)-4- QUINOLINYL]2-PYRIDINYLMETHANONE, A MEFLOQUINE INTERMEDIATE NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) 2002-12-12 US claimed
WO-2002028774-A2 CRYSTALLINE MWW-TYPE TITANOSILICATE , ITS PREPARATION AND USE THEREOF FOR PRODUCING EPOXIDES SHOWA DENKO K. K. (JP) 2002-04-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060199-A1 Cycloalkane oxidation catalysts and method to produce alcohols and ketones CBR3, ADH5, CYP2E1 NCEH1 1740/4885KMT2A 1470/4885MEN1 4825/4885
US-20020188129-A1 ONE POT SYNTHESIS OF [2, 8-BIS (TRIFLUOROMETHYL)-4- QUINOLINYL]2-PYRIDINYLMETHANONE, A MEFLOQUINE INTERMEDIATE EIF2AK2, POLK, QARS1 NCEH1 4188/4885KMT2A 618/4885MEN1 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.